**Supplementary Figure 10.** *TBC1D4* is an AR target. LNCaP cells were cotreated ± 10 μM enzalutamide (antiandrogen) with increasing concentrations of androgen (0, 100 pM or 10 nM R1881) for 24 (A) or 72 (B) h. Then, *TBC1D4* mRNA (A) or protein (B) levels were quantified using qRT-PCR and Western blot (densitometry--top, representative blots--bottom), respectively. *, significant (*P*<0.01) changes from vehicle (no androgen) treatment. #, significant (*P*<0.01) changes from vehicle (no enzalutamide) treatment.